Immunotherapy Technologies
Oncology
Preclinical/ResearchActive
Key Facts
About Kairos Pharma
Kairos Pharma is a private, clinical-stage biotech focused on overcoming two major challenges in oncology: acquired drug resistance and immune suppression. Its core platform targets the CD105 protein, identified as a central mechanism of resistance to therapies in prostate and lung cancers, and develops complementary immunomodulatory technologies. With its lead asset, ENV105, in Phase 2 trials for prostate cancer and Phase 1 for lung cancer, the company is positioned to address a significant unmet need across multiple solid tumors, backed by intellectual property protection extending to 2040.
View full company profileTherapeutic Areas
Other Oncology Drugs
| Drug | Company | Phase |
|---|---|---|
| Bi-XDC with PROTACs | Coherent Biopharma | IND-enabling |
| Bi-XDC with RPT | Coherent Biopharma | Early-stage |
| mRNA Anticancer Vaccine | Sunshine Biopharma | Preclinical Research |
| Biosimilar Bevacizumab | Organon (2) | Phase 3 |
| Biosimilar Pembrolizumab | Organon (2) | Phase 3 |
| BCL-2 Inhibitor Program | Vincerx Pharma | Preclinical |
| Not specified in provided content | 3Sbio | Various |
| Preclinical Projects | Zion Pharma | Preclinical |
| Attenukine Oncology Candidate | Teva | Phase 1 |
| XEMA Tumor Marker ELISA Kit | XEMA Group | Commercial |
| KRAS inhibitor | Risen Pharma Tech | Preclinical/Phase 1 |
| KEAP1 Activator Program | Vividion Therapeutics | Phase 1 |